Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809

A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809 is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:LADD Listeria monocytogenes bacteria JNJ-64041809
Code name:ADU-741
JNJ-64041809
JNJ-809
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search